Browsing Tag
H.C. Wainwright & Co.
2 posts
Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization
Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.
Why Digi Power X’s settlement with H.C. Wainwright closes a lingering overhang from its 2025 capital raise
Find out how Digi Power X’s settlement with H.C. Wainwright removes a financing overhang and resets investor confidence in its capital markets strategy.